NCT03730337View on ClinicalTrials.gov

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

June 28, 2021

Study Completion Date

November 22, 2022

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

ONO-7475

ONO-7475 specified dose on specified days

DRUG

ONO-7475 + ONO-4538

ONO-7475+ONO-4538 specified dose on specified days

Trial Locations (1)

Unknown

Tokyo Clinical Site, Tokyo

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY